ERBB2 and breast carcinoma: The heterogeneous nature of breast cancer and especially advanced breast cancers, and loss, mutation or other alterations of treatable markers such as ER or HER2 over time present significant challenges in finding effective diagnostic, prognostic, and therapeutic strategies [10].